Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VH5356136 Formulation 1, VH5356136 Formulation 2
VH5356136 · 1 trial · 1 indication
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A drug-related AE is an AE that, in the opinion of the investigator, is related to one of the study interventions.
The grading of AEs is performed based on the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading scale, here Grade 2 = moderate, Grade 3=severe, Grade 4 = potentially life-threatening, Grade 5 = death.
An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes.
| Arm | Type | Description |
|---|---|---|
| VH5356136 Formulation 1 | EXPERIMENTAL | Participants will receive a single dose of VH5356136 Formulation 1 administered on Day 1. |
| Placebo for VH5356136 Formulation 1 | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo for VH5356136 Formulation 1 administered on Day 1. |
| VH5356136 Formulation 2 | EXPERIMENTAL | Participants will receive a single dose of VH5356136 Formulation 2 administered on Day 1. |
| Placebo for VH5356136 Formulation 2 | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo for VH5356136 Formulation 2 administered on Day 1. |
| Name | Type | Description |
|---|---|---|
| VH5356136 Formulation 1 | DRUG | Participants will receive VH5356136 Formulation 1 on Day 1. |
| VH5356136 Formulation 2 | DRUG | Participants will receive VH5356136 Formulation 2 on Day 1. |
| Placebo for VH5356136 Formulation 1 | DRUG | Participants will receive placebo for VH5356136 Formulation 1 on Day 1. |
| Placebo for VH5356136 Formulation 2 | DRUG | Participants will receive placebo for VH5356136 Formulation 2 on Day 1. |
Inclusion Criteria: * Participants must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF). * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * ...
Top 19 of 29 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
VH5356136 is an investigational small molecule being developed by GSK plc for HIV infections. It is in Phase 1 clinical development and has not been approved by any regulatory authority. It is being studied in adult participants without HIV to assess its safety, tolerability, and pharmacokinetics.
VH5356136 is being developed for the treatment or prevention of HIV infections. It is an investigational agent and is not approved for any use. Its only clinical study to date enrolls healthy adult volunteers without HIV, so its role in HIV care has not yet been established.
VH5356136 is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the Phase 1 study evaluating the compound. The drug is an investigational small molecule and is not yet commercially available.
VH5356136 is in Phase 1 clinical development. One Phase 1 trial has been registered and is not yet recruiting, with no completed trials. Because it remains investigational, VH5356136 is not FDA approved and is not available outside of clinical research.
VH5356136 is being evaluated in one registered Phase 1 trial, NCT07822477, titled a study to investigate safety, tolerability and pharmacokinetics of VH5356136 in adult participants without HIV. The trial is not yet recruiting, plans to enroll 160 participants, and is randomized, double-blind, and placebo-controlled.
Yes. VH5356136 Formulation 1 and VH5356136 Formulation 2 are alternative names for the same investigational compound, VH5356136. These names refer to different formulations of the drug studied in the same Phase 1 program, so searches for either formulation name point to the same asset.